Which ASX biotech's shares are rocketing higher on big US news?

MotleyFool

03/24

Shares in Echo IQ Ltd (ASX: EIQ) have surged more than 13% in early trade after the company announced a revised deal with the Mayo Clinic to sell and distribute its heart failure detection software in...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2621035862"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621035862\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621035862?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 08:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621035862","market":"nz","top_or_hot":-1,"title":"Which ASX biotech's shares are rocketing higher on big US news?","media":"MotleyFool","content":"<div>\n<p>Shares in Echo IQ Ltd (ASX: EIQ) have surged more than 13% in early trade after the company announced a revised deal with the Mayo Clinic to sell and distribute its heart failure detection software in...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/24/which-asx-biotechs-shares-are-rocketing-higher-on-big-us-news/\">网页链接</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Which ASX biotech's shares are rocketing higher on big US news?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhich ASX biotech's shares are rocketing higher on big US news?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MotleyFool</strong><span class=\"h-time small\">2026-03-24 08:13</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Shares in Echo IQ Ltd (ASX: EIQ) have surged more than 13% in early trade after the company announced a revised deal with the Mayo Clinic to sell and distribute its heart failure detection software in...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/24/which-asx-biotechs-shares-are-rocketing-higher-on-big-us-news/\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.fool.com.au/2026/03/24/which-asx-biotechs-shares-are-rocketing-higher-on-big-us-news/\">MotleyFool</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://www.fool.com.au/2026/03/24/which-asx-biotechs-shares-are-rocketing-higher-on-big-us-news/","article_id":"2621035862","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/24/which-asx-biotechs-shares-are-rocketing-higher-on-big-us-news/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621035862","pubTimestamp":1774311238,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"Shares in Echo IQ Ltd  have surged more than 13% in early trade after the company announced a revised deal with the Mayo Clinic to sell and distribute its heart failure detection software in the US.Echo IQ said in a statement to the ASX on Tuesday that its EchoSolv HF technology would be deployed via the Mayo Clinic Platform – Solutions Studio Program, providing Mayo Hospitals and 80 external partner hospitals the ability to participate.The EchoSolv software is currently going through the Food & Drug Administration  clearance process, after the company lodged a market clearance application for the technology in December.The expanded agreement follows a validation study conducted through the Mayo Clinic Platform validation program. The study met its primary endpoint, with EchoSolv HF demonstrating a sensitivity of 99.5% in identifying patients with heart failure and a specificity of 91.1% in correctly identifying patients without heart failure. These results have not been reviewed or cl","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","EIQ.AU":"ECHOIQ LTD","BK7016":"应用软件"},"translate_title":"哪些ASX生物技术公司的股价因美国重大新闻而飙升？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EIQ.AU":1,"LABU":0.7},"content_text":"Shares in Echo IQ Ltd (ASX: EIQ) have surged more than 13% in early trade after the company announced a revised deal with the Mayo Clinic to sell and distribute its heart failure detection software in the US. \nEcho IQ said in a statement to the ASX on Tuesday that its EchoSolv HF technology would be deployed via the Mayo Clinic Platform – Solutions Studio Program, providing Mayo Hospitals and 80 external partner hospitals the ability to participate.\nImage source: Getty Images\nRegulatory hurdles remain\nThe EchoSolv software is currently going through the Food & Drug Administration (FDA) clearance process, after the company lodged a market clearance application for the technology in December.\nEcho IQ said further re the agreement.\n\nThe expanded agreement follows a validation study conducted through the Mayo Clinic Platform validation program. The study met its primary endpoint, with EchoSolv HF demonstrating a sensitivity of 99.5% in identifying patients with heart failure and a specificity of 91.1% in correctly identifying patients without heart failure. These results have not been reviewed or cleared by the FDA and are subject to the FDA's regulatory review process.  \n\nThe company said it would keep shareholders advised as to the progress through the FDA clearance process.\nThe company said:\n\nClearance has the potential to unlock a significant market opportunity for Echo IQ. Heart failure represents a substantial and growing burden on the US healthcare system, with about 6.7 million Americans currently living with the condition and an estimated 2 million more patients remaining undiagnosed. Upwards of 16 million echocardiograms are performed in the US per annum, with around 8 million studies containing heart failure-relevant findings, representing approximately 50% of all echocardiographic exams.\n\nConfident for the future\nEcho IQ chief executive officer Dustin Haines said the Mayo agreement was \"one of the more strategically important milestones in the company's History''.\nHe added:\n\nA more equitable arrangement with one of the most respected hospital systems in the US, as we move closer to FDA clearance and commercial deployment, leaves us well positioned for the months ahead. This milestone reflects the strength of the EchoSolv HF clinical utility and the growing commercial value of the solution, while the revised agreement provides a scalable pathway to market through the Mayo Clinic Platform. This may give us access to Mayo's hospital network and a broader ecosystem of healthcare providers seeking validated AI solutions.\n\nMr Haines said while the FDA application was still under review, the company remains confident in its submission.\nThe ASX biotech's shares were 13.8% higher in early trade at 70 cents. The shares have more than doubled in value over the past three months.\nThe company was valued at $405 million at the close of trade on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}